Easyhaler Line Breathes Life Into Ailing Orion
Expanding sales from its Easyhaler line of respiratory devices alleviated pressure on Orion in the first quarter of 2019 as the Finnish group found most of its key product franchises under pressure.
You may also be interested in...
A sluggish start to selling its salmeterol/fluticasone device in Europe did not prevent Finland’s Orion from growing its Easyhaler line of respiratory devices in the first half of 2019.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.